Genmab (GMAB) Q2 2026 Earnings Call Transcript
Genmab’s Q2 2026 earnings call set full-year 2026 revenue guidance at $4.3 billion to $4.5 billion and operating profit at $1.1 billion to $1.4 billion. DARZALEX net trade sales were $4,207 million in Q2, with EPKINLY H1 sales $312 million and proprietary portfolio revenue $396 million. Management cited Merus integration, a 3.6% effective tax rate, and multiple late-2026 readouts.
How this was made
The 30-second read
Why it matters
Raised full-year revenue and operating profit guidance, plus quantified product sales and adoption metrics, can drive expectation changes. The clinical pipeline schedule (4Q26 and 1Q27) adds catalyst-driven trading opportunities.
Market read
Traders get explicit updated 2026 guidance ranges and a near-term catalyst map for multiple oncology programs, with diversification away from DARZALEX.
What to watch
The transcript emphasizes tax-rate normalization tied to Merus integration; if integration costs or deferred tax utilization differ from expectations, margin trajectory could diverge from guidance.
Background
This is Genmab’s first-half 2026 financial results conference call transcript, covering guidance, product sales, and a clinical readout calendar.
Ticker impact
Genmab raised full-year revenue guidance to $4.3B to $4.5B and operating profit to $1.1B to $1.4B, citing higher 2026 growth and conversion.
Likely positive bias for the stock into the next readout windows, with volatility around clinical-data headlines and tax-rate normalization commentary.
The article provides explicit, time-bound financial guidance ranges and several scheduled clinical milestones in 4Q26 and 1Q27, which can re-rate expectations. However, it is a transcript and lacks consensus/market reaction context.
Market effects
Reinforces investor appetite for oncology bispecifics and ADC-adjacent platforms, especially where management ties adoption metrics to revenue durability.
European approval for TEPKINLY (second-line follicular lymphoma) supports incremental EU commercial momentum for lymphoma-focused biotechs.
Late-2026/early-2027 readout calendar can influence broader sentiment toward large-cap oncology pipelines and risk appetite for clinical-stage catalysts.
Counterpoint
Guidance upside may be partially offset by execution risk across multiple simultaneous Phase III programs and by uncertainty around the timing and magnitude of upcoming readouts.
Key entities
- companyGenmab
Biopharmaceutical company providing updated 2026 guidance, product sales metrics, and upcoming oncology readouts.
- corporate eventMerus integration
Cited as a driver of current tax-rate effects and ongoing investment levels.
- products/programsEPKINLY, DARZALEX, petosemtamab, Rina-S
Named revenue drivers and upcoming clinical readout programs that management highlighted for late-2026/early-2027 catalysts.
